A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

ClinicalTrials.gov Identifier:

NCT01227889

First received: October 21, 2010

Last updated: March 28, 2013

Last verified: March 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	June 2013
Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	January 4, 2013